Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA03 for Pseudomonas aeruginosa . The company is based in Los Angeles, California. Armata Pharmaceuticals, Inc. is a subsidiary of Innoviva, Inc. Show more

5005 McConnell Avenue, Los Angeles, CA, 90066, United States

Biotechnology

Healthcare

Market Cap

164.5M

52 Wk Range

$2.40 - $16.34

Previous Close

$4.48

Open

$4.56

Volume

4,446

Day Range

$4.50 - $4.58

Enterprise Value

459.6M

Cash

4.754M

Avg Qtr Burn

-5.782M

Insider Ownership

67.64%

Institutional Own.

13.45%

Qtr Updated

03/31/26

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
AP-SA02 Details Bacterial infection	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AP-PA02 Details Non-Cystic Fibrosis Bronchiectasis	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AP-PA02 Details Cystic fibrosis	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.